Robyn E Richardson

US Patent:

20070203236, Aug 30, 2007

Filed:

Jan 11, 2007

Appl. No.:

11/622339

Inventors:

Jeffrey Smith - Del Mar CA, US
Robyn Richardson - San Diego CA, US

International Classification:

A61K 31/202

US Classification:

514560000

Abstract:

The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.

US Patent:

20100305121, Dec 2, 2010

Filed:

May 12, 2010

Appl. No.:

12/778944

Inventors:

Jeffrey W. Smith - La Jolla CA, US
Robyn D. Richardson - La Jolla CA, US

Assignee:

Burham Institute for Medical Research - La Jolla CA

International Classification:

A61K 31/515
C07D 405/06
C07D 413/06
A61K 31/5377
C12N 5/00
G01N 33/68
A61P 35/00
A61P 3/04
A61P 19/02
A61P 17/06

US Classification:

5142345, 544300, 514270, 544116, 435375, 436 86

Abstract:

The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.

US Patent:

20220249679, Aug 11, 2022

Filed:

Oct 1, 2019

Appl. No.:

17/282368

Inventors:

- Osaka-Shi, Osaka, JP
Robyn RICHARDSON - San Diego CA, US
Anjuli TIMMER - San Diego CA, US
Roland NEWMAN - San Diego CA, US
Marco GYMNOPOULOS - San Diego CA, US

International Classification:

A61K 47/68
C07K 16/28

Abstract:

Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.

US Patent:

20200181278, Jun 11, 2020

Filed:

Apr 25, 2018

Appl. No.:

16/607492

Inventors:

- Osaka, JP
Robyn RICHARDSON - San Diego CA, US
Anjuli TIMMER - San Diego CA, US
Roland NEWMAN - San Diego CA, US

International Classification:

C07K 16/28

Abstract:

Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.